1. Home
  2. VALN vs DCTH Comparison

VALN vs DCTH Comparison

Compare VALN & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valneva SE

VALN

Valneva SE

N/A

Current Price

$6.48

Market Cap

495.5M

Sector

Health Care

ML Signal

N/A

DCTH

Delcath Systems Inc.

N/A

Current Price

$16.35

Market Cap

578.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VALN
DCTH
Founded
2012
1988
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
495.5M
578.4M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
VALN
DCTH
Price
$6.48
$16.35
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$15.50
$22.00
AVG Volume (30 Days)
77.9K
702.7K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
107.53
EPS
N/A
0.04
Revenue
N/A
N/A
Revenue This Year
N/A
$24.54
Revenue Next Year
$93.87
$33.15
P/E Ratio
N/A
$409.75
Revenue Growth
N/A
N/A
52 Week Low
$4.75
$8.12
52 Week High
$12.23
$17.42

Technical Indicators

Market Signals
Indicator
VALN
DCTH
Relative Strength Index (RSI) 60.79 58.70
Support Level $5.03 $8.57
Resistance Level $6.60 $17.42
Average True Range (ATR) 0.24 0.54
MACD 0.00 -0.15
Stochastic Oscillator 56.42 14.96

Price Performance

Historical Comparison
VALN
DCTH

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: